Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies

Oncology Reports

Volumn 16, Issue 5, 2006, Pages 1105-1110

  Looi, Koksun ^a   Megliorino, Roxanne ^a   Shi, Fu Dong ^b   Peng, Xuan Xian ^c   Chen, Yao ^a   Zhang, Jian Ying ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

Autoantibody; c myc; Cancer detection; p16; p53

Indexed keywords

AUTOANTIBODY; CANCER ANTIBODY; COMPLEMENTARY DNA; MYC PROTEIN; MYC PROTEIN, HUMAN; PROTEIN P16INK4A; PROTEIN P53; TP53 PROTEIN, HUMAN;

ANTIBODY PRODUCTION; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; METHODOLOGY; NEOPLASM;

ANTIBODIES, NEOPLASM; ANTIBODY FORMATION; AUTOANTIBODIES; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39049193999     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.16.5.1105     Document Type: Article

References (37)

1. Tan EM: Autoantibodies in pathology and cell biology. Cell 67: 841-842, 1991.
2. Tan EM: Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest 108: 1411-1415, 2001.
3. Old LJ and Chen Y-T: New paths in human cancer serology. J Exp Med 187: 1163-1167, 1998. (Pubitemid 28189106)
4. Zhang JY, Chan EKL, Peng XX, Lu M, Wang X, Mueller F and Tan EM: Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 100: 149-156, 2001.
5. Zhang JY: Tumor-associated antigen arrays to enhance antibody detection for cancer diagnosis. Cancer Detect Prev 28: 114-118, 2004.
6. Vogelstein B and Kinzler KW: The multistep nature of cancer. Trends Genet 9: 138-141, 1993. (Pubitemid 23098782)
7. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EKL and Tan EM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12: 136-143, 2003. (Pubitemid 36194003)
8. Sherr CJ and Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501-1512, 1999. (Pubitemid 29297917)
9. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D and Barrett JC: Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 93: 13742-13747, 1996. (Pubitemid 26424190)
10. Ruas M and Peters G: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378: F115- F177, 1998.
11. Soussi T: p53 antibodies in the sera of patients with various types of cancer (Review). Cancer Res 60: 1777-1788, 2000.
12. Yamamoto A, Shimizu E, Takeuchi E, Houchi H, Doi H, Bando H, Ogura T and Sone S: Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 56: 129-133, 1999. (Pubitemid 29080623)
13. Zhang JY, Chan EKL, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189: 1101-1110, 1999. (Pubitemid 29169827)
14. Zhang JY and Chan EKL: Autoantibodies to IGF-II mRNA binding protein p62 and overexpression of p62 in human hepatocellular carcinoma. Autoimmun Rev 1: 46-153, 2002.
15. Rohayem J, Diestelkoetter P, Weigle B, Oehmichen A, Schmitz M, Mehlhorn J, Conrad K and Rieber EP: Antibody response to the tumor-associated inhibitor of apoptosis protein survivin in cancer patients. Cancer Res 60: 1815-1817, 2000. (Pubitemid 30207636)
16. Megliorino R, Shi FD, Peng XX, Wang X, Chan EKL, Tan EM and Zhang JY: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 29: 241-248, 2005. (Pubitemid 40779801)
17. Pfeffer U, Fecarotta E and Vidali G: Efficient one tube RT-PCR amplification of rare transcripts using short sequence-specific reverse transcription primers. Biotechniques 18: 204-206, 1995.
18. Rubin RL: Enzyme-linked immunosorbent assays for antibodies to native DNA, histones, and (H2A-H2B)-DNA. In: Manual of Clinical Laboratory Immunology. Rose NR, Conway de Macario E, Folds JD, Lane HC and Nakamura RM (eds). 5th edition. American Society for Microbiology, Washington DC, pp935-941, 1997.
19. Chan EKL and Pollard KM: Detection of autoantibodies to ribonucleoprotein particles by immunoblotting. In: Manual of Clinical Laboratory Immunology. Rose NR, Conway de Macario E, Folds JD, Lane HC and Nakamura RM (eds). 5th edition. American Society for Microbiology, Washington, pp928-934, 1997.
20. Gordis L: Assessing the validity and reliability of diagnostic and screening tests. In: Epidemiology. Gordis L (ed). 3d edition. Elsevier Saunders, Philadelphia, pp71-94, 2004.
21. Bringold F and Serrano M: Tumor suppressors and oncogenes in cellular senescence. Exp Gerontol 35: 317-329, 2000. (Pubitemid 30314689)
22. Jen J, Harper JW, Bigner SH, et al: Vogelstein, deletion of p16 and p15 genes in brain tumors. Cancer Res 54: 6353-6358, 1994.
23. Orlow I, Lacombe L, Hannon GJ, et al: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 87: 1524-1529, 1995.
24. Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56: 3630-3633, 1996. (Pubitemid 26272001)
25. Washimi O, Nagatake M, Osada H, et al: In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in nonsmall cell lung cancers. Cancer Res 55: 514-517, 1995.
26. Feakins RM, Nickols CD, Bidd H and Walton SJ: Abnormal expression of pRb, p16 and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: relationship with pathological features and survival. Hum Pathol 34: 1276-1282, 2003. (Pubitemid 38018141)
27. Lee CT, Capodieci P, Osman I, Fazzari M, Ferrara J, Scher HI and Cordon-Cardo C: Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer. Clin Cancer Res 5: 977-983, 1999. (Pubitemid 29233210)
28. Zhao P, Hu YC and Talbot IC: Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. World J Gastroenterol 9: 2202-2206, 2003. (Pubitemid 37321445)
29. Halvorsen OJ, Hostmark J, Haukaas S, Hoisaeter PA and Akslen LA: Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88: 416-424, 2000. (Pubitemid 30051828)
30. Dong Y, Walsh MD, McGuckin MA, et al: Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product P16INK4A in ovarian cancer is associated with progression and unfavourable prognosis. Int J Cancer 74: 57-63, 1997. (Pubitemid 27157856)
31. Dublin EA, Patel NK, Gillett CE, Smith P, Peters G and Barnes DM: Retinoblastoma and p16 proteins in mammary carcinoma: their relationship to cyclin D1 and histopathological parameters. Int J Cancer 79: 71-75, 1998. (Pubitemid 28157730)
32. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, van Tornout JM and Jones PA: Methylation of the 5' CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 55: 4531-4535, 1995.
33. Jarrard DF, Bova GS, Ewing CM, et al: Deletional, mutational and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19: 90-96, 1997. (Pubitemid 27231483)
34. Shapiro GI, Edwards CD, Kobzik L, Godleski J, Richards W, Sugarbaker DJ and Rollins BJ: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55: 505-509, 1995.
35. Bartek J and Lukas J: Are all cancer genes equal? Nature 411: 1001-1002, 2001. (Pubitemid 32612305)
36. Lee YK, Park JY, Kang HJ and Cho HC: Overexpression of p16INK4A and p14ARF in haematological malignancies. Clin Lab Haematol 25: 233-237, 2003. (Pubitemid 36963184)
37. Yakut T, Egeli U and Gebitekin C: Investigation of c-myc and p53 gene alterations in the tumor and surgical borderline tissues of NSCLC and effects on clinicopathologic behavior: by the FISH technique. Lung 181: 245-258, 2003. (Pubitemid 37323732)